Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Dose-reduced Olaparib in Recurrent Ovarian Cancer
NCT04566952Phase 2Unknown
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Status: unknown.
02
Drugs
anlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04566952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566952.